Burgdorf, Switzerland – April 22, 2025 – Swiss medical technology company Ypsomed has announced the sale of its diabetes care business to TecMed AG in a deal valued at up to CHF 420 million. The move marks a significant strategic pivot as Ypsomed refocuses its efforts entirely on subcutaneous self-injection solutions for the pharmaceutical and biotech industries.

The transaction, expected to be completed in the second half of 2025 pending regulatory approval, includes the transfer of Ypsomed Diabetes Care AG and its subsidiaries, along with patch pump development programs and associated rights.

A Clean Split for Greater Focus

TecMed AG, also based in Burgdorf and controlled by entrepreneur Willy Michel, emerged as the winning bidder in a structured sale process that began in November 2024. The new entity will integrate Ypsomed’s established insulin infusion offerings, including the mylife Loop system and mylife YpsoPump, with TecMed’s patch pump technology to form a dedicated leader in insulin delivery.

“Two specialized companies will be more focused, more agile, and ultimately more successful,” said Ypsomed CEO Simon Michel.

The integration will maintain headquarters in Burgdorf and house roughly 300 employees. Around 200 Ypsomed staff members currently based in Solothurn will relocate, allowing Ypsomed to expand operations at its main site to meet growing demand for its autoinjector systems.

Doubling Down on Injection Systems

The divestment will fuel Ypsomed’s investment in automated manufacturing and global expansion of its self-injection device business. “We are focusing on capturing substantial opportunities in the subcutaneous self-injection market,” Michel stated, citing the rise of biologics and biosimilars as key growth drivers.

Ypsomed will also reallocate resources from its discontinued pen needle business and a concluded contract manufacturing agreement with Sanofi to further strengthen production capacity.

A Vision for Diabetes Innovation

TecMed aims to build on Ypsomed’s legacy in diabetes management. “We want to empower people with diabetes through choice and innovation,” said Patrick Schär, designated Chief Corporate Services Officer at TecMed. “Combining our patch pump development with Ypsomed’s proven systems positions us to meet growing demand for insulin infusion technologies.”

The transition is designed to ensure continuity for patients, healthcare professionals, and employees, while preserving Ypsomed’s deep regional roots in Switzerland.